ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study examined the association between metformin-based oral antihyperglycemic combination therapy and the risk of developing dementia in patients with newly diagnosed type 2 diabetes mellitus (T2DM).
methodsWe conducted a retrospective cohort study using data from a random sample of 2,000,000 individuals in Taiwan's National Health Insurance Research Database from 2000 to 2018. A total of 44,073 patients with newly diagnosed T2DM were identified and categorized into four groups based on initial treatment: metformin (MET)-sulfonylureas (SU), MET-dipeptidyl peptidase-4 inhibitor (DPP4i), MET-thiazolidinedione (TZD), and MET-glinides. The participants were followed until December 2018.
resultsThe hazard ratio of MET-TZD was 0.73 (95% confidence interval [CI]: 0.57-0.94), of MET-DPP4i was 0.64 (95% CI: 0.52-0.79), and of MET-glinides was 1.14 (95% CI: 0.94-1.39). DISCUSSION: The MET-DPP4i group had the lowest risk of dementia, followed by the MET-TZD group. HIGHLIGHTS: Newly diagnosed type 2 diabetes mellitus (T2DM) patients using metformin (MET)-glinides and MET-sulfonylureas are at an increased risk of dementia. The MET-glinides group had the highest risk of dementia. The MET-dipeptidyl peptidase-4 inhibitor group had the lowest risk of dementia, followed by the MET-thiazolidinedione group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.